Afya (NASDAQ:AFYA) VP Lelio De Souza Junior Sells 41,541 Shares

Afya Limited (NASDAQ:AFYA) VP Lelio De Souza Junior sold 41,541 shares of Afya stock in a transaction on Friday, June 26th. The shares were sold at an average price of $15.00, for a total value of $623,115.00. Following the sale, the vice president directly owned 36,204 shares in the company, valued at $543,060. The trade was a 53.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Lelio De Souza Junior also recently made the following trade(s):

• On Thursday, April 9th, Lelio De Souza Junior sold 16,279 shares of Afya stock. The stock was sold at an average price of $14.53, for a total value of $236,533.87.
• On Tuesday, April 7th, Lelio De Souza Junior sold 26,753 shares of Afya stock. The stock was sold at an average price of $14.95, for a total value of $399,957.35.

Afya Stock Performance

Shares of AFYA traded down $0.03 during trading hours on Tuesday, reaching $14.84. 109,181 shares of the company’s stock traded hands, compared to its average volume of 105,793. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of 9.70, a P/E/G ratio of 1.53 and a beta of 0.34. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.78 and a quick ratio of 1.78. Afya Limited has a twelve month low of $13.00 and a twelve month high of $18.16. The business’s fifty day simple moving average is $14.33 and its two-hundred day simple moving average is $14.52.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Zacks Research cut shares of Afya from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 6th. Bank of America reiterated a “neutral” rating on shares of Afya in a report on Thursday, June 11th. Wall Street Zen lowered shares of Afya from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. dropped their target price on Afya from $21.50 to $21.00 and set a “neutral” rating on the stock in a report on Monday, June 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Afya in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $17.10.

Hedge Funds Weigh In On Afya

Several hedge funds have recently made changes to their positions in AFYA. Swedbank AB raised its holdings in shares of Afya by 170.3% in the 4th quarter. Swedbank AB now owns 189,200 shares of the company’s stock worth $2,916,000 after purchasing an additional 119,200 shares in the last quarter. SPX Gestao de Recursos Ltda bought a new stake in Afya during the third quarter worth approximately $2,895,000. Doma Perpetual Capital Management LLC grew its position in Afya by 50.6% in the third quarter. Doma Perpetual Capital Management LLC now owns 891,639 shares of the company’s stock worth $13,910,000 after buying an additional 299,419 shares during the last quarter. Quantbot Technologies LP acquired a new position in Afya in the second quarter worth approximately $117,000. Finally, Militia Capital Partners LP bought a new position in shares of Afya in the second quarter valued at $71,000. Institutional investors and hedge funds own 88.02% of the company’s stock.

About Afya

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.